Mineralys Therapeutics To Present New Long-Term Efficacy And Safety Data From Ongoing Transform-HTN Open-Label Extension Trial Of Aldosterone Synthase Inhibitor Lorundrostat At AHA Scientific Sessions 2026
Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney
Mineralys will show new safety and effectiveness data for its blood pressure medicine. When a company shares positive long-term results, it can help people feel more confident about the drug.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.